Streptomycin
- Generic Name
- Streptomycin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C21H39N7O12
- CAS Number
- 57-92-1
- Unique Ingredient Identifier
- Y45QSO73OB
- Background
Streptomycin, an antibiotic derived from Streptomyces griseus, was the first aminoglycoside to be discovered and used in practice in the 1940s. Selman Waksman and eventually Albert Schatz were recognized with the Nobel Prize in Medicine for their discovery of streptomycin and its antibacterial activity. Although streptomycin was the first antibiotic determin...
- Indication
Although streptomycin was the first antibiotic available for the treatment of mycobacterium tuberculosis, it is now largely a second line option due to resistance and toxicity. Streptomycin may also be used to treat a variety of other infections caused by susceptible strains of aerobic bacteria where other less toxic agents are ineffective. Examples include:...
- Associated Conditions
- Bacteremia, Bacterial Infections caused by susceptible bacteria, Chancroid, Disseminated mycobacterium avium complex infection, Flu caused by Influenza, Granuloma Inguinale, Menière's Disease, Mycobacterium Avium Intracellulare Complex (MAC), Mycobacterium kansasii infection, Mycobacterium marinum infection, Plague, Pneumonia, Tuberculosis (TB), Tularemia, Urinary Tract Infection
- Associated Therapies
- -
Ciprofloxacin Versus an Aminoglycoside Followed by Ciprofloxacin for Bubonic Plague
- Conditions
- Interventions
- First Posted Date
- 2019-10-01
- Last Posted Date
- 2024-06-17
- Lead Sponsor
- University of Oxford
- Target Recruit Count
- 463
- Registration Number
- NCT04110340
- Locations
- 🇲🇬
Professor Mamy Randria, Antananarivo, Madagascar
Efficacy of Intestinal Decontamination in Patients Colonized by Carbapenem-resistant Klebsiella Pneumoniae and Colistin
- Conditions
- Interventions
- First Posted Date
- 2015-11-13
- Last Posted Date
- 2015-11-13
- Target Recruit Count
- 44
- Registration Number
- NCT02604849
Treatment and Diagnosis of Plague
- Conditions
- First Posted Date
- 2005-08-10
- Last Posted Date
- 2009-02-26
- Lead Sponsor
- Centers for Disease Control and Prevention
- Target Recruit Count
- 114
- Registration Number
- NCT00128466
- Locations
- 🇲🇬
Ministry of Health, Antananarivo, Madagascar
Phase II Study of Amithiozone (Thiacetazone) for Patients With Mycobacterium Avium Complex Pulmonary Disease
- Conditions
- First Posted Date
- 2000-02-25
- Last Posted Date
- 2015-03-25
- Lead Sponsor
- National Jewish Health
- Target Recruit Count
- 50
- Registration Number
- NCT00004689
Pilot Randomized Study of Paromomycin (Aminosidine) vs Streptomycin for Uncomplicated Pulmonary Tuberculosis
- Conditions
- First Posted Date
- 1999-10-19
- Last Posted Date
- 2015-03-25
- Lead Sponsor
- FDA Office of Orphan Products Development
- Target Recruit Count
- 24
- Registration Number
- NCT00004444
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.